Literature DB >> 21483645

Rare variant mutations identified in pediatric patients with dilated cardiomyopathy.

Evadnie Rampersaud1, Jill D Siegfried, Nadine Norton, Duanxiang Li, Eden Martin, Ray E Hershberger.   

Abstract

Dilated cardiomyopathy (DCM) in infants and children can be partially explained by genetic cause but the catalogue of known genes is limited. We reviewed our database of 41 cases diagnosed with DCM before 18 years of age who underwent detailed clinical and genetic evaluation, and summarize here the evidence for mutations causing DCM in these cases from 15 genes (PSEN1, PSEN2, CSRP3, LBD3, MYH7, SCN5A, TCAP, TNNT2, LMNA, MYBPC3, MYH6, TNNC1, TNNI3, TPM1, and RBM20). Thirty-five of the 41 pediatric cases had relatives with adult-onset DCM. More males (66%) were found among children diagnosed after 1 year of age with DCM. Nineteen mutations in 9 genes were identified among 15 out of 41 patients; 3 patients (diagnosed at ages 2 weeks, 9 and 13 years) had multiple mutations. Of the 19 mutations identified in 12 families, mutations in TPM1 (32%) and TNNT2 (21%) were the most commonly found. Of the 6 patients diagnosed before 1 year of age, 3 had mutations in TPM1 (including a set of identical twins), 1 in TNNT2, 1 in MYH7, and 1 with multiple mutations (MYH7 and TNNC1). Most DCM was accompanied by advanced heart failure and need for cardiac transplantation. We conclude that in some cases pediatric DCM has a genetic basis, which is complicated by allelic and locus heterogeneity as seen in adult-onset DCM. We suggest that future prospective comprehensive family-based genetic studies of pediatric DCM are indicated to further define mutation frequencies in known genes and to discover novel genetic cause.

Entities:  

Year:  2011        PMID: 21483645      PMCID: PMC3072577          DOI: 10.1016/j.ppedcard.2010.11.008

Source DB:  PubMed          Journal:  Prog Pediatr Cardiol        ISSN: 1058-9813


  41 in total

1.  Clinical characteristics of 304 kindreds evaluated for familial dilated cardiomyopathy.

Authors:  Jessica D Kushner; Deirdre Nauman; Donna Burgess; Susan Ludwigsen; Sharie B Parks; George Pantely; Emily Burkett; Ray E Hershberger
Journal:  J Card Fail       Date:  2006-08       Impact factor: 5.712

2.  Incidence, causes, and outcomes of dilated cardiomyopathy in children.

Authors:  Jeffrey A Towbin; April M Lowe; Steven D Colan; Lynn A Sleeper; E John Orav; Sarah Clunie; Jane Messere; Gerald F Cox; Paul R Lurie; Daphne Hsu; Charles Canter; James D Wilkinson; Steven E Lipshultz
Journal:  JAMA       Date:  2006-10-18       Impact factor: 56.272

3.  Natural history of dilated cardiomyopathy due to lamin A/C gene mutations.

Authors:  Matthew R G Taylor; Pamela R Fain; Gianfranco Sinagra; Misi L Robinson; Alastair D Robertson; Elisa Carniel; Andrea Di Lenarda; Teresa J Bohlmeyer; Debra A Ferguson; Gary L Brodsky; Mark M Boucek; Jean Lascor; Andrew C Moss; Wai Lun P Li; Gary L Stetler; Francesco Muntoni; Michael R Bristow; Luisa Mestroni
Journal:  J Am Coll Cardiol       Date:  2003-03-05       Impact factor: 24.094

4.  Lamin A/C mutation analysis in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy.

Authors:  Sharie B Parks; Jessica D Kushner; Deirdre Nauman; Donna Burgess; Susan Ludwigsen; Amanda Peterson; Duanxiang Li; Petra Jakobs; Michael Litt; Charles B Porter; Peter S Rahko; Ray E Hershberger
Journal:  Am Heart J       Date:  2008-03-12       Impact factor: 4.749

5.  Coding sequence mutations identified in MYH7, TNNT2, SCN5A, CSRP3, LBD3, and TCAP from 313 patients with familial or idiopathic dilated cardiomyopathy.

Authors:  Ray E Hershberger; Sharie B Parks; Jessica D Kushner; Duanxiang Li; Susan Ludwigsen; Petra Jakobs; Deirdre Nauman; Donna Burgess; Julie Partain; Michael Litt
Journal:  Clin Transl Sci       Date:  2008-05       Impact factor: 4.689

6.  Genetic evaluation of cardiomyopathy--a Heart Failure Society of America practice guideline.

Authors:  Ray E Hershberger; Joann Lindenfeld; Luisa Mestroni; Christine E Seidman; Matthew R G Taylor; Jeffrey A Towbin
Journal:  J Card Fail       Date:  2009-03       Impact factor: 5.712

7.  Johanson-Blizzard syndrome caused by identical UBR1 mutations in two unrelated girls, one with a cardiomyopathy.

Authors:  Mariet Elting; Ariana Kariminejad; Marie-Louise de Sonnaville; Jaap Ottenkamp; Susanne Bauhuber; Bita Bozorgmehr; Martin Zenker; Jan M Cobben
Journal:  Am J Med Genet A       Date:  2008-12-01       Impact factor: 2.802

8.  Morphological analysis of 13 LMNA variants identified in a cohort of 324 unrelated patients with idiopathic or familial dilated cardiomyopathy.

Authors:  Jason Cowan; Duanxiang Li; Jorge Gonzalez-Quintana; Ana Morales; Ray E Hershberger
Journal:  Circ Cardiovasc Genet       Date:  2009-11-17

9.  Severe disease expression of cardiac troponin C and T mutations in patients with idiopathic dilated cardiomyopathy.

Authors:  Jens Mogensen; Ross T Murphy; Tony Shaw; Ajay Bahl; Charles Redwood; Hugh Watkins; Margaret Burke; Perry M Elliott; William J McKenna
Journal:  J Am Coll Cardiol       Date:  2004-11-16       Impact factor: 24.094

10.  C-terminal titin deletions cause a novel early-onset myopathy with fatal cardiomyopathy.

Authors:  Virginie Carmignac; Mustafa A M Salih; Susana Quijano-Roy; Sylvie Marchand; Molham M Al Rayess; Maowia M Mukhtar; Jon A Urtizberea; Siegfried Labeit; Pascale Guicheney; France Leturcq; Mathias Gautel; Michel Fardeau; Kevin P Campbell; Isabelle Richard; Brigitte Estournet; Ana Ferreiro
Journal:  Ann Neurol       Date:  2007-04       Impact factor: 10.422

View more
  36 in total

1.  The cardiomyopathy-associated K15N mutation in tropomyosin alters actin filament pointed end dynamics.

Authors:  Mert Colpan; Thu Ly; Samantha Grover; Dmitri Tolkatchev; Alla S Kostyukova
Journal:  Arch Biochem Biophys       Date:  2017-07-18       Impact factor: 4.013

2.  Clinical utility gene card for: dilated cardiomyopathy (CMD).

Authors:  Anna Posafalvi; Johanna C Herkert; Richard J Sinke; Maarten P van den Berg; Jens Mogensen; Jan D H Jongbloed; J Peter van Tintelen
Journal:  Eur J Hum Genet       Date:  2012-12-19       Impact factor: 4.246

Review 3.  The Rationale and Timing of Molecular Genetic Testing for Dilated Cardiomyopathy.

Authors:  Ana Morales; Ray E Hershberger
Journal:  Can J Cardiol       Date:  2015-07-09       Impact factor: 5.223

Review 4.  Pre-mRNA mis-splicing of sarcomeric genes in heart failure.

Authors:  Chaoqun Zhu; Zhilong Chen; Wei Guo
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2016-11-05       Impact factor: 5.187

Review 5.  Importance of genetic evaluation and testing in pediatric cardiomyopathy.

Authors:  Muhammad Tariq; Stephanie M Ware
Journal:  World J Cardiol       Date:  2014-11-26

6.  Presenilin 1 is a direct regulator of the cardiac sarco/endoplasmic reticulum calcium pump.

Authors:  Elisa Bovo; Roman Nikolaienko; Daniel Kahn; Ellen Cho; Seth L Robia; Aleksey V Zima
Journal:  Cell Calcium       Date:  2021-09-05       Impact factor: 6.817

7.  Pediatric and adult dilated cardiomyopathy represent distinct pathological entities.

Authors:  Meghna D Patel; Jayaram Mohan; Caralin Schneider; Geetika Bajpai; Enkhsaikhan Purevjav; Charles E Canter; Jeffrey Towbin; Andrea Bredemeyer; Kory J Lavine
Journal:  JCI Insight       Date:  2017-07-20

Review 8.  Genotype-phenotype associations in dilated cardiomyopathy: meta-analysis on more than 8000 individuals.

Authors:  Elham Kayvanpour; Farbod Sedaghat-Hamedani; Ali Amr; Alan Lai; Jan Haas; Daniel B Holzer; Karen S Frese; Andreas Keller; Katrin Jensen; Hugo A Katus; Benjamin Meder
Journal:  Clin Res Cardiol       Date:  2016-08-30       Impact factor: 5.460

Review 9.  Genetic evaluation of dilated cardiomyopathy.

Authors:  Ana Morales; Ray E Hershberger
Journal:  Curr Cardiol Rep       Date:  2013-07       Impact factor: 2.931

10.  Insulin regulates titin pre-mRNA splicing through the PI3K-Akt-mTOR kinase axis in a RBM20-dependent manner.

Authors:  Chaoqun Zhu; Zhiyong Yin; Bihua Tan; Wei Guo
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-07-01       Impact factor: 5.187

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.